For patients with chronic viral hepatitis B, if there is an elevation of glutathione and glutamic oxalacetic aminotransferase in liver function, the patient should have further blood tests for hepatitis B triple system and hepatitis B DNA, to see if the patient’s hepatitis B triple system indicates a major triple-positive condition, and if the patient’s hepatitis B DNA indicates viral replication. If the patient indicates that the virus is replicating, and there is a combination of elevated glutamic acid and glutamic oxalacetic aminotransferase, the patient is considered to be in the window of viral replication and needs to be actively considered for antiviral treatment along with liver preservation therapy. The liver-protective drugs can choose diammonium glycyrrhizate and hepatocyte-producing hormone, while the antiviral treatment drugs can choose oral tenofovir and entecavir, and can also actively consider injecting interferon for antiviral treatment. During the treatment period, patients should pay attention to more rest, do not stay up late, do not strain, and absolutely do not drink alcohol. The patient’s viral replication can be controlled through active liver protection therapy, antiviral therapy and lifestyle changes, and the patient’s glutamic and glutamic aminotransferases will mostly drop to normal.